| E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00400829) | National Cancer Institute (NCI) | 2006-11-01 |
| Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab (NCT00387374) | National Cancer Institute (NCI) | 2006-10-01 |
| S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer (NCT00368992) | National Cancer Institute (NCI) | 2006-08-01 |
| Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer (NCT00387465) | National Cancer Institute (NCI) | 2006-08-01 |
| IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer (NCT00300586) | Hospices Civils de Lyon | 2006-06-01 |
| Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer (NCT00950365) | Albert Einstein College of Medicine | 2006-04-01 |
| Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00408460) | University of Washington | 2006-02-01 |
| Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer (NCT00247416) | Susanne Arnold | 2005-08-01 |
| Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (NCT00118183) | National Cancer Institute (NCI) | 2005-07-01 |
| Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer (NCT00118144) | National Cancer Institute (NCI) | 2005-06-01 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NCT00138203) | National Cancer Institute (NCI) | 2005-06-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655) | Mayo Clinic | 2004-12-01 |
| Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00098540) | National Cancer Institute (NCI) | 2004-12-01 |
| Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NCT00085280) | National Cancer Institute (NCI) | 2004-09-01 |
| S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer (NCT00087412) | National Cancer Institute (NCI) | 2004-09-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer (NCT00084981) | National Cancer Institute (NCI) | 2004-04-01 |
| STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) (NCT00088088) | Synta Pharmaceuticals Corp. | 2004-03-01 |
| CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer (NCT00079235) | National Cancer Institute (NCI) | 2004-02-01 |
| Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer (NCT00075751) | National Cancer Institute (NCI) | 2004-01-01 |
| Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer (NCT00062101) | National Cancer Institute (NCI) | 2004-01-01 |
| Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00088959) | National Cancer Institute (NCI) | 2003-12-01 |
| Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (NCT00055757) | National Cancer Institute (NCI) | 2003-10-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer (NCT00066768) | National Cancer Institute (NCI) | 2003-07-01 |
| Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine (NCT00228358) | University of Washington | 2003-06-01 |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck (NCT00063895) | National Cancer Institute (NCI) | 2003-04-01 |
| Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer (NCT00052338) | National Cancer Institute (NCI) | 2002-09-01 |
| Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer (NCT00021060) | National Cancer Institute (NCI) | 2002-08-01 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) (NCT00042315) | QLT Inc. | 2002-06-01 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) (NCT00042302) | QLT Inc. | 2002-06-01 |
| Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer (NCT00040768) | National Cancer Institute (NCI) | 2002-04-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (NCT00039091) | National Cancer Institute (NCI) | 2002-03-01 |
| Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00029003) | National Cancer Institute (NCI) | 2001-12-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer (NCT01004731) | University of Alabama at Birmingham | 2001-06-01 |
| Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (NCT00006929) | National Cancer Institute (NCI) | 2000-09-01 |
| FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer (NCT00020202) | National Cancer Institute (NCI) | 2000-06-01 |
| Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 (NCT00004883) | National Cancer Institute (NCI) | 2000-02-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer (NCT00003869) | National Cancer Institute (NCI) | 1999-04-01 |
| Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT00003497) | Burzynski Research Institute | 1996-08-21 |